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Tumor-specific T cell receptor (TCR) gene transfer enables specific
and potent immune targeting of tumor antigens. Due to the
prevalence of the HLA-A2 MHC class I supertype in most human
populations, the majority of TCR gene therapy trials targeting public
antigens have employed HLA-A2–restricted TCRs, limiting this ap-
proach to those patients expressing this allele. For these patients,
TCR gene therapy trials have resulted in both tantalizing successes
and lethal adverse events, underscoring the need for careful selec-
tion of antigenic targets. Broad and safe application of public
antigen-targeted TCR gene therapies will require (i) selecting public
antigens that are highly tumor-specific and (ii) targeting multiple
epitopes derived from these antigens by obtaining an assortment of
TCRs restricted by multiple commonMHC alleles. The canonical cancer-
testis antigen, NY-ESO-1, is not expressed in normal tissues but is
aberrantly expressed across a broad array of cancer types. It has
also been targeted with A2-restricted TCR gene therapy without
adverse events or notable side effects. To enable the targeting of
NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs
specific for NY-ESO-1 epitopes presented by four MHC molecules:
HLA-A2, -B07, -B18, and -C03. Using these TCRs, we pilot an ap-
proach to extend TCR gene therapies targeting NY-ESO-1 to pa-
tient populations beyond those expressing HLA-A2.
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The αβ T cell receptor (TCR) determines the unique speci-ficity of each nascent T cell. Upon assembly with CD3 signaling
proteins on the T cell surface, the TCR surveils peptide ligands
presented by MHC molecules on the surface of nucleated cells.
The specificity of the TCR for a peptide–MHC complex is de-
termined by both the presenting MHC molecule and the presented
peptide. TheMHC locus (also known as the HLA locus in humans)
is the most multiallelic locus in the human genome, compris-
ing >18,000MHC class I and II alleles that vary widely in frequency
across ethnic subgroups (1, 2). Ligands presented by MHC class I
molecules are derived primarily from proteasomal cleavage of
endogenously expressed antigens. Infected and cancerous cells
present peptides that are recognized by CD8+ T cells as foreign or
aberrant, resulting in T cell-mediated killing of the presenting cell.
T cells can be engineered to kill tumor cells through the
transfer of tumor-reactive αβ TCR genes (3). Key to this ap-
proach is that the patient expresses the MHC allele on which the
therapeutic TCR is restricted and that the targeted peptide is
derived from a tumor-associated or tumor-specific antigen. Pri-
vate (patient-specific) neoantigens resulting from tumor-specific
mutations are a potential source of such targets (4). However,
implementation of personalized TCR gene therapy is compli-
cated by the need to identify mutations through sequencing, to
isolate mutation-reactive, patient-specific TCRs, and to geneti-
cally modify patient T cells on demand. This is still more chal-
lenging for tumors that cannot be accessed for sequencing and
for low-mutational-burden tumors with few or no neoantigens
(5). Particularly for these last tumor types, targeting public,
tumor-restricted antigens with off-the-shelf TCRs remains an
attractive option.
The first public antigen targeted with TCR gene therapy in the
clinic was melanocyte antigen MART1/Melan-A, yielding ob-
jective responses in 2/15 patients with metastatic melanoma (6).
Use of a higher-affinity MART1-reactive TCR (F5) increased
the response rate to 30% but also engendered vitiligo, uveitis,
and transient hearing loss due to MART1 expression on healthy
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melanocytes in the skin, eye, and middle ear (7). T cell therapies
targeting other public antigens have similarly engendered mor-
bidity or serious adverse events due to on-target/off-tumor reactivity.
Targeting carcinoembryonic antigen produces severe colitis in pa-
tients with metastatic colorectal cancer due to reactivity with nor-
mal colorectal tissue (8). More seriously, T cell therapies targeted at
ERBB2 orMAGE-A3 each resulted in deaths due to unappreciated
expression of the target antigen (or similar variant) on vital organs
(9, 10). Thus, these studies underscore the importance of identi-
fying stringently tumor-specific public antigens (11), particularly
when well-expressed, high-affinity targeting receptors necessary
for therapeutic success are employed (7, 12).
NY-ESO-1—the product of the CTAG1B gene—is an attrac-
tive target for off-the-shelf TCR gene therapy. As the pro-
totypical cancer-testis antigen, NY-ESO-1 is not expressed in
normal, nongermline tissue, but it is aberrantly expressed in
many tumors (13). The frequency of aberrant expression ranges
from 10 to 50% among solid tumors, 25–50% of melanomas, and
up to 80% of synovial sarcomas (13–18), with increased expres-
sion observed in higher-grade metastatic tumor tissue (14, 15,
19). Moreover, NY-ESO-1 is highly immunogenic, precipitating
spontaneous and vaccine-induced T cell immune responses
against multiple epitopes presented by various MHC alleles (20–
23). As a result, the epitope NY-ESO-1157–165 (SLLMWITQC)
presented by HLA-A*02:01 has been targeted with cognate 1G4
TCR in gene therapy trials, yielding objective responses in 55%
and 61% of patients with metastatic melanoma and synovial
sarcoma, respectively, and engendering no adverse events related
to targeting (24, 25). Targeting this same A2-restricted epitope
with lentiviral-mediated TCR gene therapy in patients with
multiple myeloma similarly resulted in 70% complete or near-
complete responses without significant safety concerns (26). The
majority of patients who respond to therapy relapse within
months, and loss of heterozygosity at the MHCI locus has been
reported as a mechanism by which tumors escape adoptive T cell
therapy targeting HLA-A*02:01/NY-ESO-1157–165 (27). Thus,
NY-ESO-1 is a tumor-specific, immunogenic public antigen that
is expressed across an array of tumor types and is safe to target in
the clinic but that is susceptible to escape when targeted through
a single HLA subtype.
In this work, we had two goals. First, since TCRs of higher
strength and affinity are more efficacious, we sought to identify
new TCRs that target A2/NY157–165 with comparable or better
sensitivity than the clinically employed 1G4 TCR. As affinity-
enhanced TCRs can be cross-reactive (28–30), we established a
protocol for isolating antigen-reactive TCRs directly from patient
blood. Two of these TCRs demonstrated comparable or greater
sensitivity than 1G4 both in vitro and in vivo in tumor-killing as-
says. Second, to broaden the clinical utility of NY-ESO-1 as a TCR
gene therapy target, we used our isolation protocol to identify
TCRs that target NY-ESO-1 epitopes presented by commonMHC
alleles other than HLA-A*02:01. We propose that targeting mul-
tiple NY-ESO-1 epitopes will enable treatment of a larger patient
set and may render treatment more robust toward tumor escape.
Results
Expansion and Isolation of NY-ESO-1–Specific T Cell Clones. We
previously reported the presence of T cells reactive with various
NY-ESO-1–derived epitopes in the blood of patients with meta-
static melanoma (22). To enrich for these reactive T cells, we
stimulated expansion of patient peripheral blood mononuclear
cells (PBMCs) with a panel of 28 overlapping 18-mers collectively
constituting the full NY-ESO-1 protein sequence (Fig. 1A). We
then restimulated the expanded cells with individual peptides,
performed intracellular staining for IFN-γ to determine which
peptides drove expansion, and analyzed stimulatory peptides with
a predictive algorithm to identify minimal epitopes relevant to
each patient’s MHC haplotype (31) (Fig. 1B). Reactive T cells
were reexpanded in the presence of individual 9–10-mer peptides
corresponding to immunostimulatory epitopes (Fig. 1C) and sor-
ted via FACS using cognate peptide–MHC tetramers (Fig. 1D).
The cell lines grown from these single-cell sorts were clonal and
reactive with their cognate epitopes (Fig. 1E). In total, four cell
lines reactive with HLA-A*02:01/NY157–165 and four cell lines
reactive with epitopes presented by HLA-B and HLA-C alleles
were selected for further study.
Cloning and Screening of NY-ESO-1–Specific TCRs.We cloned paired
TCRα and TCRβ genes from sorted single cells using a com-
mercial RT-PCR kit with custom multiplexed primers targeting
all human TRAV and TRBV gene segments. The resulting Vα
and Vβ cDNAs were subcloned into a retroviral vector backbone
with either human or murine TCR constant regions (Fig. 2A). To
verify the specificity of cloned TCRs, we transfected CD3+ HEK
293T cells with each fully human TCR and stained the trans-
fected cells with peptide–MHC dextramer reagents for each of
the targeted NY-ESO-1 epitopes (Fig. 2B). All four HLA-A2–
restricted TCRs exhibited the expected reactivity (Fig. 2C). Al-
though analyzed events were gated for similar transfection level,
novel TCRs exhibited highly variable dextramer binding. Dex-
tramer binding for the 9D2 TCR was barely discernible from
background, whereas the 3A1 TCR exhibited superior dextramer
binding compared with the clinically employed 1G4 TCR. Dex-
tramer binding for 4A2 and 5G6 TCRs were intermediate be-
tween 9D2 and 1G4.
Additionally, three of four of the TCRs restricted on MHC
alleles other than HLA-A2 were verified to bind their targets
specifically (Fig. 2D). Transfected 293T cells expressing the B7/
NY60–72-specific 1E4 TCR, the B18/NY88–96-specific 2B8 TCR,
or the Cw3/NY96–104-specific 3C7 TCR each bound their re-
spective dextramers, whereas untransfected cells did not. Cells
transfected with the 9G2 TCR—cloned from T cells that were
reactive with Cw3/NY92–100—did not detectably bind cognate
dextramer relative to untransfected cells. A possible reason for
this was that HEK 293T cells do not express the CD8 coreceptor.
CD8 increases the avidity of the TCR–pMHC interaction by
binding to MHCI directly, enabling lower affinity TCRs to en-
gage (32). We therefore included this TCR for further analysis of
CD8 dependency in Jurkat T cells.
Functional Characterization of A2-Restricted, NY-ESO-1–Specific TCRs.
The sensitivity of a TCR-transduced T cell is a function of the
monomeric affinity of the TCR for its cognate peptide–MHC (Kd
∼ 0.1–400 μM) (33) as well as the density of the TCR on the cell
surface (12). Transduced TCRs express on the T cell surface at
widely varying levels due to variation in the efficiency with which
they fold, dimerize, and compete with endogenous TCRs for
assembly with limiting CD3 chains (a property termed TCR
“strength”) (34, 35). Therefore, optimal cytotoxic function of
TCR-transduced T cells correlates with TCR affinity and surface
expression (3, 12), underscoring the importance of selecting
high-affinity, efficiently exported TCRs for gene therapy (7).
As higher-affinity TCR–pMHC interactions are less de-
pendent on CD8 participation, we reasoned that high-affinity
TCRs can be identified by comparing dextramer binding of
TCR-transduced Jurkat T cells with or without coexpression of
CD8. Additionally, because the strength of surface expression for
human TCRs can be increased through substitution with murine
constant domains (36), we expressed each TCR as a fully human
or murinized derivative to assess each TCR’s strength. Cells
transduced with vehicle only or with a mismatched TCR
(MART1-specific F5 TCR) did not exhibit any binding to A2/
NY157–165 dextramer (Fig. 3 A and B). By contrast, cells trans-
duced with the well-established 1G4 TCR (Kd = 9.3 μM) (37)
bound cognate dextramer whether 1G4 was fully human or
murinized, and whether or not CD8 was present. Murinization of
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1G4 increased the intensity of dextramer binding by the muTCR
1.4-fold over the parental huTCR, indicating a modest improve-
ment in strength (Fig. 3 B and C). The presence of CD8 increased
dextramer binding 3.8-fold for 1G4 muTCR. Dextramer binding
for TCRs 4A2 and 5G6 was similar in both magnitude and com-
parative indices to 1G4 (Fig. 3 A–C). The 3A1 TCR exhibited only
a 1.9-fold increase in dextramer binding in the presence of CD8,
indicating that this TCR binds A2/NY157–165 with higher affinity
than 1G4. This is further supported by the reduced dependence of
dextramer binding on CD8 level among CD8+ cells transduced
with 3A1 muTCR relative to CD8+ cells transduced with 1G4,
4A2, and 5G6 muTCRs (compare slopes of green populations in
Fig. 3A). Finally, 9D2 exhibited no detectable binding to dex-
tramer on Jurkat cells in the absence of CD8 and only weak
binding upon coexpression of CD8. Murinization of 9D2 did not
increase its binding to dextramer.
To compare the functional sensitivity of T cells expressing A2/
NY-ESO-1–specific TCRs we coincubated TCR-transduced Jurkat
T cells with K562 cells expressing either A*02:01/NY157–165 or
A*02:01/MART127–35 single-chain trimers (38) and measured se-
creted IL-2. All TCRs exhibited their expected peptide specificity:
The control MART1-specific F5 TCR mediated IL-2 release only
in response to MART1 presentation and all NY-ESO-1–specific
TCRs mediated IL-2 release only in response to NY-ESO-1 pre-
sentation (Fig. 3D). Murinization improved functional sensitivity
for all TCRs except for 1G4. Consistent with dextramer staining
Fig. 1. Expansion and isolation of NY-ESO-1–spe-
cific T cell clones. PBMCs were obtained from pa-
tients with metastatic melanoma. T cell cloning
strategy for a representative HLA-A2+, HLA-Cw3+
donor is shown. (A) Schematic outlining the expan-
sion and testing strategy to identify NY-ESO-1–re-
active T cell clones. PBMCs were incubated with 28
NY-ESO-1 18-mer peptides (overlapping by 12 aa)
and then expanded for 10 d before restimulation
with individual peptides in the presence of BFA. Epi-
topes presented by patient MHC alleles are colored
red, blue, and green in those peptides containing the
full epitope sequence. (B) Representative flow cytom-
etry measurement of intracellular staining for IFN-γ in
expanded PBMCs restimulated with individual NY-ESO-
1–derived 18-mer peptides. (C) Schematic outlining the
reexpansion strategy using individual 9–10-mer pep-
tides verified to elicit a T cell response. (D) Representa-
tive flow cytometry data showing an NY-ESO-1–reactive
subpopulation of CD3+CD8+ T cells before sorting.
Sorted cells were expanded in the presence of IL-2 and
irradiated autologous PBMCs. (E) Representative flow
cytometry data showing an NY-ESO-1–reactive sub-
population of CD3+CD8+ T cells following sorting.
Fig. 2. Cloning and functional screening of NY-ESO-1–specific TCRs. (A) Schematic of functional TCR cloning strategy. For each TCR, two constructs were
prepared incorporating either human or murine TCR constant domains. (B) Protein sequence of NY-ESO-1 with epitopes relevant to this study delineated. (C)
Flow cytometry histograms comparing HLA-A2/NY157–165 dextramer binding by HEK 293T cells transfected with vector backbone only, previously reported 1G4
TCR, and novel A2-restricted, NY-ESO-1–specific TCRs. (D) Flow cytometry histograms comparing indicated peptide–MHC dextramer binding by HEK 293T cells
transfected with vector backbone only or the indicated novel NY-ESO-1-specificNY-ESO-1–specific TCR restricted on MHC alleles other than HLA-A2. Trans-
fection experiments were performed twice, each in duplicate. Representative histograms are presented.
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results, 1G4 and 3A1 muTCRs outperformed 4A2 and 5G6muTCRs.
By contrast, despite its weak binding to dextramer, 9D2 exhibited
high functional sensitivity to cognate ligand, comparable to 3A1.
To quantify this observation, we pulsed A2+K562 cells with varied
concentrations of NY-ESO-1157–165 or MART127–35 peptide and
then measured IFN-γ secretion from TCR-transduced primary
T cells coincubated with peptide-pulsed target cells (SI Appendix,
Fig. S1 A and B). As observed with single-chain trimer targets,
3A1, 9D2, and 1G4 exhibited highest sensitivity to NY-ESO-1157–165
peptide. The functional sensitivity of 9D2 was 10-fold higher than
4A2, despite 4A2 binding dextramer with 18-fold higher MFI than
9D2 (Fig. 3 A and B). To evaluate responses to endogenously
processed and presented antigen, TCR-transduced primary T cells
were coincubated with the human melanoma cell line, A2+M257
(Fig. 3E). Again, T cells transduced with 3A1, 9D2, and 1G4
responded comparably to one another, and with higher sensitivity
than did those transduced with 5G6 and 4A2. TCR-transduced
T cells did not respond to the M257 line lacking HLA-A*02:01.
Finally, in vitro cytotoxicity tracked closely with cytokine release:
T cells expressing 9D2 or 3A1 killed A2+M257 tumor cells most
efficiently, followed by T cells transduced with 1G4, 5G6, and,
least efficiently, 4A2 (Fig. 3F).
To enable evaluation of TCR function in a tumor xenograft
model, we engineered the PC-3 human prostate cancer cell line
to express NY-ESO-1 and HLA-A*02:01 and then verified that
this line elicited functional responses from TCR-transduced
T cells in an antigen-dependent and MHC-restricted manner
(SI Appendix, Fig. S2A). The relative responses to A2+NY+PC-
3 from our panel of NY-ESO-1–reactive TCRs were consistent
with those elicited by A2+M257 (Fig. 3E and SI Appendix, Fig.
S2B). Based on these results, we selected 1G4, 3A1, and
9D2 muTCRs for further functional characterization in vivo. We
transduced activated human PBMCs with a vector encoding each
murinized TCR and a transduction marker [low-affinity nerve
growth factor receptor (LNGFR)] (Fig. 4A). We sorted trans-
duced (CD3+LNGFR+) T cells (SI Appendix, Fig. S2C) and
retroorbitally i.v. injected these T cells into irradiated NOD/
SCID/γc−/− (NSG) mice preinoculated with PC-3/HLA-A2 (control)
and PC-3/HLA-A2/NYESO (target) tumors on opposing flanks
(Fig. 4B). We then monitored T cell engraftment and tumor size
until the conclusion of the experiment 2 wk after T cell injection.
T cells transduced with 1G4 or 9D2 TCRs persisted or mini-
mally expanded in the peripheral blood, while 3A1-transduced
T cells expanded significantly (Fig. 4 C and D). By contrast,
T cells transduced only with LNGFR contracted over the course
Fig. 3. Function of A2-restricted, NY-ESO-1–specific TCRs. (A) Overlay of representative flow cytometry plots comparing A2/NY157–165 dextramer binding by Jurkat
and CD8+ Jurkat cells expressing A2-restricted TCRs with human or murine constant domains. (B) Dextramer binding mean fluorescence intensity measurements
from two independent experiments as in A. (C) Ratio of dextramer binding mean fluorescent intensity measurements from two independent experiments in B. (D)
ELISA measuring secretion of IL-2 from TCR-transduced Jurkat cells following 48-h coincubation with K562 target cells expressing A2/MART26–35 or A2/NY157–165
single-chain trimer. Experiment was repeated three times, each with two technical replicates. Means ± SD for a representative experiment are shown. (E) ELISA
measuring secretion of IFN-γ from TCR-transduced PBMCs following 48-h coincubation with the melanoma cell line M257 or an A2+ derivative. Experiment was
repeated at least three times, each with two technical replicates. Means ± SD for a representative experiment are shown. (F) IncuCyte measurement of total green
object area over time as a measurement of TCR-transduced T cell-mediated killing of GFP+ A2+ M257 cells. Means ± SD for four technical replicates are shown.
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of the experiment, suggesting the expansion of TCR-transduced
T cells was antigen-driven. The expression level of murine TCRβ
was stable over the experimental time course and comparable
between T cells transduced with different murinized TCRs (Fig.
4 C and E). The respective staining levels of each TCR-
transduced T cell cohort with A*02:01/NY157–165 dextramer
+
were also stable over time, but, as expected from results in vitro,
were significantly different between TCRs. Approximately 90% of
Fig. 4. In vivo antitumor efficacy of NY-ESO-1 TCR–engineered human T cells. (A and B) Schematics of the experimental designs to (A) generate NY-ESO-1
TCR–engineered human T cells and to (B) study antitumor efficacy of these engineered T cells in an NSG mouse human prostate tumor xenograft model. NSG,
immunodeficient NOD/SCID/γc−/− mice. (C) Representative flow cytometry plots characterizing engineered human T cells present in the peripheral blood of
experimental mice on day 14 after adoptive T cell transfer. (D) Time course showing persistence of engineered human T cells (gated as LNGFR+ hCD45+) in the
peripheral blood of experimental mice. (E and F) Mean fluorescence intensity measurements for (E) murine TCR and (F) HLA-A2/NYESO dextramer for
engineered human T cells in the peripheral blood of experimental mice on day 14 after adoptive T cell transfer. (G and H) Measurements of cross-sectional
area for (G) PC-3/HLA-A2 and (H) PC-3/HLA-A2/NYESO tumors. (I) Immunohistology images showing representative tumor sections. CD3+ cells are stained in
red. (Scale bars: Upper, 500 μm; Lower, 50 μm.) (J) Percentage of CD3+ cell area over whole tumor section area. Representative of two experiments. Data are
presented as the mean ± SEM (n = 4–5). ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, by one-way ANOVA.
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human T cells transduced with 1G4 or 3A1 were dextramer+ with
high MFI. By contrast, only ∼1% of 9D2-transduced T cells were
dextramer+ and the MFI of staining was not significantly dif-
ferent from LNGFR-transduced controls (Fig. 4 C and F).
Nonetheless, T cells transduced with 1G4, 3A1, or 9D2 reduced
tumor size comparably and in an antigen-specific manner, while
LNGFR-transduced T cells failed to control tumor growth (Fig.
4 G and H).
At the conclusion of the experiment, we killed the mice and
analyzed tumors for T cell infiltration by immunohistochemistry.
Immunohistochemical staining revealed antigen-specific T cell
infiltration only into target tumors in all cohorts receiving TCR-
transduced T cells (Fig. 4 I and J). Infiltration was significantly
higher in mice receiving 3A1-transduced T cells relative to mice
receiving 1G4- or 9D2-transduced T cells.
Functional Characterization of NY-ESO-1–Specific TCRs Restricted on
HLA-B and HLA-C Alleles. The majority of immunotherapies tar-
geting NY-ESO-1 have focused on the A2-restricted NY157–165
epitope. To enable broader application of NY-ESO-1–targeted
immunotherapies, we cloned TCRs from four non-A2-restricted
T cell clones and verified NY-ESO-1 reactivity for three of these
in transfected CD3+ 293T (Fig. 2D). The fourth TCR—9G2,
cloned from Cw3/NY92–100-reactive T cells—did not impart
specificity for Cw3/NY92–100 on transduced Jurkat T cells even
with coexpressed CD8 (Fig. 5 A and B) and was not studied
Fig. 5. Function of NY-ESO-1–specific TCRs restricted on MHC alleles other than HLA-A2. (A) Overlay of representative flow cytometry plots comparing
specified dextramer binding by Jurkat and CD8+ Jurkat cells expressing novel TCRs with human or murine constant domains. (B) Indicated dextramer binding
mean fluorescence intensity measurements from two independent experiments as in A. (C) Ratio of respective dextramer binding mean fluorescent intensity
measurements from two independent experiments in B. (D and E) ELISA measuring (D) secretion of IL-2 from TCR-transduced Jurkat cells or (E) secretion of
IFN-γ from TCR-transduced PBMCs following 48-h coincubation with K562 target cells expressing indicated single-chain trimer. Experiments were repeated
three times, each with two technical replicates. Means ± SD for a representative experiment are shown.
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further. Comparisons of dextramer binding by the three vali-
dated TCRs expressed in Jurkat or CD8+ Jurkat as human or
murine TCRs revealed differences in strength and affinity (Fig. 5
A–C). The B7/NY60–72-specific 1E4 TCR exhibited high strength
but low affinity, expressing comparably on the Jurkat cell surface
as either a huTCR or a muTCR but binding dextramer only in
the presence of CD8+. Dextramer binding to these CD8+, 1E4-
transduced cells was steeply dependent on the level of CD8
expressed. By contrast, the B18/NY88–96-specific 2B8 TCR
bound dextramer in the absence of CD8+, but binding was sub-
stantially higher for the murinized TCR. Finally, the Cw3/NY96–104-
specific 3C7 TCR exhibited intermediate strength of surface ex-
pression and an affinity index comparable to 2B8.
These differences in TCR strength and affinity were reflected in
functional assays. For all three TCRs, murinization of the TCR
constant regions increased production of IL-2 from TCR-transduced
Jurkat cells coincubated with cognate target cells. However, this
increase was only 1.6- and 3.0-fold over the respective fully human
TCRs for 1E4 and 3C7 but was 18.6-fold for 2B8, consistent with the
latter’s lower strength (Fig. 5D). In peptide titration assays, 1E4
TCR imparted lower sensitivity for cognate peptide on transduced
CD8+ T cells than did 3C7 or 2B8 (SI Appendix, Fig. S1 C–E),
consistent with the presumed lower affinity of 1E4 based on its
strictly CD8-dependent dextramer binding.
Primary PBMCs transduced with each TCR responded to the
presentation of NY-ESO-1–derived epitopes in a peptide-
specific and MHC-restricted manner (Fig. 5E). As such, we ex-
pect that TCR gene therapies employing NY-ESO-1–specific
TCRs restricted on multiple MHCs can be applied more broadly
across patient haplotypes and will be more robust toward tumor
evasion via loss of heterozygosity at the MHCI locus. To test this,
we transduced NY-ESO-1–expressing human cancer cells with
HLA-A2 or HLA-B7. We then coincubated one or both of these
tumor targets with human T cells transduced with A2-restricted
3A1 TCR, with T cells transduced with B7-restricted 1E4 TCR,
or with a mixture of 3A1- and 1E4-transduced T cells (Fig. 6). As
expected, combination targeting using a mixture of 3A1- and
1E4-transduced T cells enabled recognition of tumor cell pop-
ulations expressing both MHC alleles or either MHC allele alone
(Fig. 6 A and B). By contrast, T cells targeting a single NY-ESO-
1 epitope did not respond to NY-ESO-1–expressing tumor cells
that lacked the cognate MHC allele. Moreover, when tumor
targets comprised a mixture of cells expressing different MHC
alleles (simulating tumor heterogeneity arising from hap-
loinsufficiency), T cells targeting both NY-ESO-1 epitopes killed
tumor cells more completely than did T cells targeting either
single epitope (Fig. 6 C and D).
Discussion
T cell-mediated immunotherapies are making clinical inroads for
previously refractory cancers. Two of the most successful im-
munotherapy modalities are checkpoint blockade and adoptive
transfer of cancer-specific T cells. Checkpoint blockade elicits
better clinical responses as tumor mutational burden increases
(39–41), suggesting that nonsynonymous mutations go undetected
by the immune system unless, fortuitously, they generate neoepitopes
that are presented by the patient’s complement of MHC mole-
cules. This interpretation is bolstered by the recent finding that
checkpoint blockade results in higher overall survival for mela-
noma patients who are heterozygous at the HLA-A, HLA-B, and
HLA-C loci and thus present a more diverse array of epitopes
than those who are homozygous at one or more of these MHCI
loci (42). The importance of a diversely targeted antitumor im-
mune response is likewise supported by results from adoptive T cell
therapy, which show that loss of heterozygosity is a mechanism by
which tumors can evade monospecific immune recognition while
continuing to express an otherwise immunogenic antigen (43). Thus,
a prominent narrative emerging from these studies is that diverse
targeting of multiple epitopes presented by multiple MHC alleles
is desirable for successful immunotherapy. A second takeaway is
that targeting multiple epitopes derived from a tumor-specific
public antigen may be a promising alternative to targeting neo-
epitopes in cancers with low mutational burden.
It has proven difficult to identify public tumor-associated an-
tigens that mediate tumor regression without also manifesting
serious morbidity or deaths resulting from on-target, off-tumor
T cell reactivity. We chose to focus on NY-ESO-1 as a public
antigenic target based on the criteria that it (i) is expressed ex-
clusively in cancer cells and immunologically privileged germ
cells; (ii) is expressed in many patients across various tumor
types; (iii) harbors high-affinity ligands for multiple common
MHC alleles; (iv) is well-vetted, having yielded objective re-
sponses in patients across several tumor types without specificity-
related adverse events; and (v) is yet underexploited, as the
majority of studies have focused on mobilizing T cell responses
solely against the A2-restricted NY-ESO-1157–165 epitope.
We employed an antigen-specific expansion protocol to isolate
NY-ESO-1–reactive T cells from the peripheral blood of patients
with metastatic melanoma. Using this approach, we cloned sev-
eral HLA-A2–restricted TCRs and compared them in terms of
their strength of surface expression, affinity (i.e., dependence of
target binding on CD8), and function (antigen-induced cytokine
release and tumor target killing). From four candidates, we
identified two that recognized and killed NY-ESO-1–expressing
cancer cells as well or better than the clinically employed 1G4
TCR. This expansion-based approach to TCR candidate identi-
fication is ideally suited for targeting public epitopes because the
speed of isolation is not a critical parameter; once identified,
these TCRs can be used as off-the-shelf targeting receptors for
any patient expressing the requisite MHC allele. Antigen-specific
expansion of neoantigen-reactive T cells from peripheral blood
has also been demonstrated (44, 45). However, on-demand iso-
lation of private neoepitope-targeted TCRs will require more
rapid approaches than that used here (e.g., direct capture of
antigen-specific T cells from blood or expansion protocols opti-
mized for rapidity). As the release of IFN-γ is strongly correlated
with cytotoxicity (46), candidate evaluation can be accelerated by
using IFN-γ release as a surrogate for more involved tumor
xenograft assays.
One of the HLA-A2/NY-ESO-1–reactive TCRs isolated—
9D2—exhibited poor staining with cognate multimer but high
functional avidity toward cognate antigen-presenting target cells.
This is consistent with the observation that multimer staining
underestimates functional T cell subsets (47) and may be
explained by the higher-affinity threshold for multimer binding
relative to that for T cell activation (48). However, another
isolated A2-restricted TCR—4A2—exhibited robust multimer
staining but poor function in cell-based assays, seemingly at odds
with this affinity threshold explanation. While we do not have an
explanation for this latter result, both results caution against
relying too much on multimer staining when down-selecting
immunotherapy candidates.
The HLA-A*02:01 allele is the most prevalent MHCI allele in
Caucasian (45%) and Hispanic (41%) US populations, but it is
less common among Asian (15%) and African (16%) US pop-
ulations (2). These latter populations would be particularly well-
served by expanding the targeting of TCR gene therapies beyond
HLA-A2 to a more expansive panel of targetable MHC alleles.
In addition to HLA-A2–restricted TCRs, we isolated and func-
tionally characterized NY-ESO-1–specific TCRs restricted on
various HLA-B and HLA-C alleles. In doing so, we demon-
strated in principle that TCR gene therapy can be extended to a
greater subset of patients/haplotypes and that, when used in
combination, TCRs recognizing multiple epitopes from the same
antigen can more robustly kill tumors with heterogeneous MHC
expression (e.g., resulting from somatic loss of heterozygosity).
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Over 80% of people across ethnic groups express at least one
allele from three MHCI supertypes (A2, A3, and B7, two of
which were represented here) and >99% of people express at
least one allele from nine MHCI supertypes (49). Therefore,
obtaining a panel of public antigen-specific TCR reagents that
enable comprehensive application of TCR gene therapy is a fi-
nite and surmountable challenge.
Materials and Methods
Materials. Peptides were purchased from Anaspec, Thermo Fisher Scientific,
and Mimotopes. Fluorescent antibodies and 7-AAD used for flow cytometry
were purchased from BD Biosciences, BioLegend, or eBioscience. Fluorescent
peptide–MHC multimers were purchased from TCMetrix or prepared in-
house as described (50) from biotinylated monomers [obtained from NIH
Tetramer Core, or expressed heterologously in Escherichia coli, refolded, and
biotinylated in-house as described (51)]. Primers were purchased from In-
tegrated DNA Technologies. KOD polymerase master mix and polybrene
were purchased from EMD Millipore. Sequencing was performed by Retro-
gen Inc. Anti-CD3 (OKT3) and anti-CD28 (CD28.2) activating antibodies were
purchased from eBioscience. Cytokines were purchased from Peprotech, Inc.
BioT transfection reagent was purchased from Bioland Scientific. Cell culture
media, antibiotics, and FBS were purchased from Corning. Human AB serumwas
purchased from Omega Scientific. Poly-L-lysine and PHA-L (phytohemagglutinin-
L) were purchased from Sigma.
Cells. Cell lines (293T/17, Jurkat E6-1, and K562) were purchased from the
American Type Culture Collection. The 293T cells were grown in DMEM
supplemented with antibiotics (penicillin/streptomycin) and 10% (vol/vol)
FBS. Jurkat and K562 cells were grown in RPMI medium 1640 supplemented
with antibiotics, 10% (vol/vol) FBS, 10 mM Hepes, 50 μM β-mercaptoethanol,
1× MEM NEAA, and 1 mM sodium pyruvate. The cells were split every 2–3 d
to maintain adherent cells subconfluently or nonadherent cells at a density
of <106 cells/mL Jurkat and K562 cells were transduced with nonreplicative
viral vectors, analyzed by flow cytometry, and used directly in cell assays or
sorted by FACS to establish derivative cell lines as indicated. Primary human
PBMCs used in functional assays were purchased from the CFAR Virology
Core Laboratory at the University of California, Los Angeles (UCLA) AIDS
Institute, stimulated, transduced, and cultured as previously described (52).
T cells were grown from PBMCs in T cell medium (AIM-V medium supple-
mented with 5% heat-inactivated human AB serum, 55 μM β-mercaptoe-
thanol, and 4 mM L-glutamine) with freshly added cytokines. All cells were
grown and assayed at 37 °C with 5% atmospheric CO2.
Fig. 6. Targeting NY-ESO-1 epitopes restricted on multiple MHC alleles broadens the application of TCR gene therapy and makes it robust toward loss of
heterozygosity at the MHC locus. (A–D) T cells transduced with LNGFR only, A2-restricted 3A1 TCR, or B7-restricted 1E4 TCR—or a 1:1 mixture of 3A1-
transduced and 1E4-transduced T cells—were coincubated for 48 h with HLA-A2+eGFP+ target cells, HLA-B7+eGFP+ target cells, or a 1:1 target cell mixture. (A
and B) ELISA measuring secretion of IFN-γ from TCR-transduced PBMCs following 48-h coincubation with (A) M257 or (B) PC-3 tumor cell lines engineered to
express eGFP and HLA-A*02:01 or HLA-B*07:02. PC-3 lines were additionally engineered to express NY-ESO-1. M257 lines express endogenous NY-ESO-1.
Experiments were repeated three times, each with four or eight replicates. Means ± SD for a representative experiment are shown. (C and D) T cell-mediated
killing of (C) M257 and (D) PC-3 tumor cell line derivatives measured over time using IncuCyte live-cell analysis. Total green object area (indicative of tumor
cell density) at each time point measured over 48 h was normalized for each treatment relative to treatment with LNGFR-transduced T cells. Experiments were
repeated three times, each with four or eight replicates. Results from a representative eight-replicate experiment are shown.
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Generation and Culture of NY-ESO-1–Specific CD8+ T Lymphocyte Clones. CD8+
T lymphocyte clones specific for epitopes from NY-ESO-1 with various HLA
restrictions [157–165/HLA-A*02:01 (53), 60–72/HLA-B*07:02 (21), 88–96/HLA-
B*18:01 (23), 92–100/HLA-C*03:04 (54), 96–104/HLA-C*03:04 (22), and 124–
133/HLA-C*03:04 (22)] were generated from HLA-typed patients with mel-
anoma. All selected patients had grade III/IV metastatic melanoma and
previously documented NY-ESO-1 responses to relevant T lymphocyte epi-
topes ex vivo (55). Patient PBMCs were stimulated in the presence of 1 μM
pooled peptides (Mimotopes), comprising 28 × 18-mers overlapping by
12 aa, collectively spanning the NY-ESO-1 protein sequence and then cul-
tured for 10 d in the presence of 25 IU/mL IL-2 (Peprotech).
On day 10, cells were restimulated with 1 μM of each individual peptide in
the presence of brefeldin A and activation of CD8+ T cells in response to each
peptide was determined by intracellular cytokine stain. Briefly, cells were
labeled with live/dead fixable violet stain (Invitrogen) according to the
manufacturer’s instructions then incubated with antibodies against CD3 and
CD8 for 15 min at 4 °C. Samples were washed and fixed with fix/per-
meabilization reagent (BD Biosciences) for 20 min at 4 °C. Cells were stained
with anti–IFN-γ (eBiosciences) in permeabilization/wash solution (BD Biosciences)
for 25 min at 4 °C. The gating strategy was SSC/LD−; CD3+/CD8+; CD8+/IFN-γ+.
Data from at least 100,000 stained cells were acquired on a FACSCanto and
analyzed with FlowJo software. Data collection and analysis was in accordance
with the Minimal Information About T cell Assays guidelines (56).
NY-ESO-1–reactive T cells were expanded in the presence of their iden-
tified cognate 9–10-mer epitope and then labeled with a fluorescent tet-
ramer comprising the relevant peptide and HLA molecule (TCMetrix) and
single-cell-sorted using a MoFlo cell sorter. Clones were reexpanded with
pooled, allogeneic healthy donor PBMC as feeder cells, 1 μg/mL PHA-L, and
600 IU/mL IL-2 (Cetus). After ∼20 d, 1–10 × 103 clones were restimulated in
the presence of allogeneic PBMC as feeder cells, PHA-L, and IL-2, as described
above. Clone specificity was confirmed by tetramer staining.
T lymphocyte clones/lines were cultured in RPMI 1640 media supple-
mented with 2 mM Glutamax, 100 IU/mL penicillin, 100 μg/mL streptomycin,
20 mM Hepes, 1% nonessential amino acids, 1 mM sodium pyruvate, 55 μM
β-mercaptoethanol, and 10% human serum (TCRPMI). IL-2 (100 IU/mL) was
added and replaced every 3 d.
Cloning TCR Constructs. Single NY-ESO-1–reactive T cells were sorted for
antigenic specificity on a FACS Aria II and were lysed by freeze–thaw in the
presence of RNase inhibitor. Novel TCR variable genes were cloned from
single, sorted T cells using a custom panel of human TCR variable region-
specific primers with the Qiagen OneStep RT-PCR kit, followed by a nested
PCR amplification step. Amplified variable genes were integrated via as-
sembly PCR and restriction enzyme-mediated cloning into a TCR expression
cassette with either human or mouse TCR constant domains and a 2A ri-
bosomal skipping peptide linking the alpha and beta genes. A P2A-linked
gene encoding a truncated version of the LNGFR was also included in the
cassette as an independent transfection/transduction marker. Antigenic
specificity and MHC restriction of cloned TCRs were evaluated in 293T cells
cotransfected with TCR and CD3 genes, as previously described (52).
Evaluation of TCR Export and Dextramer Binding on Jurkat T Cells. Jurkat T cells
were transduced with MSGV-based retroviruses encoding each novel TCR in
the format LNGFRΔ-P2A-TCRα-F2A-TCRβ. Viruses were produced in 293T cells
as described (52). For transduction, Jurkat T cells were centrifuged (1,350 × g
for 90 min at 30 °C) with unconcentrated viral supernatants supplemented
with 5 μg/mL polybrene. TCR-transduced Jurkat cells were stained with
cognate pMHC dextramer for 15 min at room temperature and then costained
with antibodies against LNGFR and CD8α for 15 min at 4 °C. Stained cells were
analyzed by flow cytometry using a FACSCanto analyzer. Data shown are
gated on LNGFR+ (transduced) cells. Transduction efficiency was >95%.
PBMC Activation and Transduction. Primary human PBMCs were purchased
from the CFAR Virology Core Laboratory at the UCLAAIDS Institute. The same
PBMC donor was used in all reported experiments. Primary human PBMCs
were transduced with retroviruses encoding novel TCRs as described (52).
Briefly, 2 d before viral transduction, 1–2 × 106 total thawed PBMCs were
activated per well in 24-well plates with plate-coated anti-CD3 (clone OKT3),
T cell medium containing 1 μg/mL soluble anti-CD28 (clone CD28.2), and
300 U/mL IL-2. After 48 h of activation, the majority of the medium was
replaced with unconcentrated retroviral supernatant supplemented with
10 μg/mL polybrene and cells were centrifuged for 90 min at 1,350 × g at 30 °C.
Following spinfection, the majority of retroviral supernatant was replaced with
fresh medium containing 300 U/mL IL-2 and 1 μg/mL anti-CD28. The trans-
duction was repeated 24 h later, after which the cells were washed with 1× PBS
and then returned to fresh medium containing final 300 U/mL IL-2 and cultured
for an additional 3–4 d before being used in antigenic stimulation assays. One day
before or on the day of coculturing, PBMCs were analyzed by FACS for assessment
of expression levels for LNGFR, TCR, and/or pMHC multimer binding.
Functional Coculture Assays: Cytokine ELISA. When Jurkat T cells were used as
effectors, cocultures were performed in RPMI supplemented with 10% FBS,
100 IU/mL penicillin, 100 μg/mL streptomycin, and 4 mM L-glutamine. Effector
cells (50,000 TCR-transduced Jurat T cells) were coincubated with target cells
(50,000 K562 cells transduced with cognate or control single-chain trimers) in
96-well flat-bottom plates. Supernatants from duplicate wells were collected
44–48 h postcoculturing and analyzed by ELISA as described below.
When primary PBMCs were used as effectors, cocultures were performed in
T cell media containing 300 U/mL IL-2. Effector cells (50,000 TCR-transduced
PBMCs) were coincubated with target cells (50,000 M257, PC-3, or K562 cells)
in 96-well flat-bottom plates. In some experiments target cells were pulsed with
peptide. Supernatants from twoeightfold replicatewells for each conditionwere
collected 44–48 h postcoculturing and analyzed by ELISA as described below.
For experiments in which target cells were titrated with pulsed peptide,
lyophilizedpeptidesweredissolved to 10mMinDMSOand then further diluted
inwater to 2mMworking stocks. At point of use, the 2mMstockwas diluted to
250 μM in cell media and then fivefold serially diluted from 250 μM down to
3.2 nM. Target cells were pulsed by adding 25 μL of each serial dilution per
well on a 96-well U-bottom plate, followed by addition of 50,000 target cells in
100 μL media, yielding the final peptide concentration ranging from 50 μM to
0.64 nM. Cells were pulsed with peptides for 2 h at 37 °C, diluted with 100 μL
of media per well at the end of incubation, and centrifuged, and the super-
natant was removed. The cells were washed with 200 μL of media and then
resuspended in 100 μL of media. Fifty thousand PBMCs prepared in 100 μL of
media were then added to each well for coculturing.
In general, ELISA results were converted to concentration (nanograms per
milliliter) by interpolation relative to a standard curve and concentrations from
replicate ELISAs were averaged. Supernatants were diluted 50- to 100-fold
for ELISA analysis. Occasionally, higher dilutions were required to place
signal within the range of the standard curve. All reagents for ELISA
analyses were from BD Biosciences: OptEIA Reagent Set B (550534) was used
for diluent and washes and OptEIA human IFN-γ ELISA kit (555142) and
OptEIA human IL-2 ELISA kit (555190) were used for measuring IFN-γ and
IL-2 release, respectively.
Functional Coculture Assays: IncuCyte Cell Killing Assay. Before coculture for
IncuCyte killing assays, a 96-well flat-bottom plate was coated with 100 μL of
0.001% poly-L-lysine in PBS for 1 h at 37 °C, washed two times with 200 μL
PBS each, and air-dried briefly. Target cells were added and allowed to settle
at room temperature for 3 h before the effector cells were added. Cocul-
tures typically employed 25,000 PBMCs and 25,000 target cells per well of a
96-well plate. In assays where multiple effector populations (bearing dif-
ferent TCRs) or multiple targets (bearing different MHC) were mixed,
25,000 of each cell type was used to yield a total of 75,000 or 100,000 cells
per well (for single/mixed or mixed/mixed, respectively). The total volume
for all wells was adjusted to 200 μL. Total green object area (square micro-
meters per well) was quantified and its disappearance interpreted as killing
of the GFP+ target cells. Cells were imaged at two positions per well every
2 h and these two images were added together for one data point. Data
points obtained from four to eight replicate cocultures for each effector/
target combination were used to plot graph curves and to calculate SD.
Animals. NOD.Cg-PrkdcSCIDIL-2rgtm1Wjl/SzJ (NOD/SCID/IL-2Rg−/−, NSG) mice
were purchased from The Jackson Laboratory and maintained in the animal
facilities at UCLA. Adult (16 wk old) male mice were used for in vivo tumor
challenge experiments. All animal experiments were approved by the In-
stitutional Animal Care and Use Committee of UCLA.
Human Prostate Tumor Xenograft Mouse Model. For xenograft tumor implan-
tation, 10 × 106 PC-3/HLA-A2 cells (PC-3 cell line overexpressing HLA-A2) were s.c.
injected on one flank of each mouse and 10 × 106 PC-3/HLA-A2/NYESO cells (PC-
3 cell line overexpressing HLA-A2 and NYESO) were s.c. injected on the other
flank. Mice were allowed to develop solid tumors over the course of 1 wk. On
day 8 after tumor injection, mice were irradiated (100 rad) and then retro-
orbitally i.v. injected with 8 × 106 purified T cells that were engineered to express
LNGFR only or together with a NY-ESO-1–specific TCR (1G4, 3A1, or 9D2). Mice
were bled on days 3, 7, 10, and 14 for flow cytometry analysis. On day 14, mice
were killed and tumors were collected for immunohistology analysis.
Bethune et al. PNAS Latest Articles | 9 of 10
M
ED
IC
A
L
SC
IE
N
CE
S
Immunohistology. Solid tumors dissected out from the experimental mice
were fixed in 10% neutral-buffered formalin and embedded in paraffin for
sectioning (4-mm thickness), followed by H&E staining or antibody staining
(for human CD3e) by using standard procedures (UCLA Translational Pa-
thology Core Laboratory). The sections were imaged using an Olympus
BX51 upright microscope equipped with an Optronics Macrofire CCD camera
(AU Optronics) at 4× and 40× magnifications. The images were analyzed by
using Optronics PictureFrame software (AU Optronics) and ImageJ software
(version 1.51J8). With ImageJ human CD3 antibody-stained slides were quan-
tified by measuring CD3+ area through setting color threshold. Parameters
used are as follows: thresholding method: default; threshold color: red; color
space: HSB; brightness: 168–215.
Statistical Analysis. Statistical analysis of tumor xenograft experiments was
performedwith one-way ANOVA followed by Tukey’s multiple comparison test.
Data are presented as the mean ± SEM. P < 0.05 was considered significant. ns,
not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. All statistical
analyses were performed with GraphPad PRISM software (version 6.0).
Ethics Statement. All samples used were IRB-approved and deidentified for all
work reported in our study; the research protocol was approved by Austin
Health Human Research Ethics Committee (HREC H2006/02633).
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